Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.
about
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the StriatumRibosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to FunctionDopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonismTargeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingThe extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review).Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysAstrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian miceA Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB ExpressionDopaminergic tone regulates transient potassium current maximal conductance through a translational mechanism requiring D1Rs, cAMP/PKA, Erk and mTOR.Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling.Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsDifferential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesiaDopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism.Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsIntrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease.Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's diseaseMaladaptive Synaptic Plasticity in L-DOPA-Induced DyskinesiaMechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.G protein-coupled receptor kinases as regulators of dopamine receptor functions.The protease Omi cleaves the mitogen-activated protein kinase kinase MEK1 to inhibit microglial activation.Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.Synaptic plasticity may underlie l-DOPA induced dyskinesia.
P2860
Q21284508-96698A4F-D3CD-4368-BAF4-D37CAD91D214Q26770762-049A4D86-3447-4BE1-8F92-D3AEB124CDD4Q27313903-B740DECF-F058-4C76-A8EE-5DE9249F3B9FQ27324174-2F831D72-F9B3-45D0-AD52-0F804F64B2AFQ28582674-384D9948-1799-4842-8129-6D392207BA5DQ33674924-010D99A5-1E32-4FAC-B24E-7A22634DA440Q33835745-9045FFDB-8C87-41D0-A9F5-575AA17DE5DEQ34186299-62FD598F-D591-4586-B765-76BAEE847396Q34238909-9535AAC7-8FA8-4153-8A61-60795A10E82FQ34490801-8AB206C6-4941-458C-B0EA-E963B484EFC1Q35024117-48CEDE3C-2F07-4DA9-A7E0-1496E8F7445AQ35041795-0E305DA4-09FB-470C-9CEE-235658D21EDBQ35106605-E79D9234-1955-4153-B1EB-9B987824F126Q35208420-3436BBD9-BE56-4FAC-A339-91762D0258FEQ35424424-E25C16A2-0579-4AAE-A2EE-6A7672D092F7Q35575588-AE225AE5-FF10-42F1-B5AE-009EEB94D0B8Q35740152-771E6087-1003-4B18-A334-3B1842CE007EQ35777273-4124E179-7433-4356-9628-FDB7E9920976Q36201811-511ADAB4-0B73-4C7C-A920-1F9387BBAE3CQ36422521-116EB2C7-21EA-484F-92D6-434E79E91FF6Q36557687-D5ACAA3C-4BA3-4FDD-9752-22A1BF433A0AQ37115808-8E9FDB10-71E6-4AFC-A048-8C194BAC9A9DQ37301208-38682598-21E6-40B8-82A5-ABB5F2732CE2Q37516434-CAF2130D-CEE7-4D4D-9065-BC7BDE7C75E7Q37924629-4829DF42-8017-4D10-A5FA-A537AC4D0D93Q37925513-E6681105-15BE-4AD2-A908-F6D2ADBC23ABQ37974709-A01ED02E-4114-40F1-A39C-337159CD8706Q38056852-E66A62F5-029B-4E6F-8276-8809F6DECA52Q38190016-F4527EA5-A9F0-46A8-8849-301E40B5B61BQ38262418-40DEBAB9-08EF-4DD8-899E-B904230485F4Q38834292-DAA85201-3466-46F5-8503-643311E09C76Q39293229-BA74F488-A703-422A-9EE7-214D9AFBD4E0Q42512289-971CC254-DF82-4A6C-9E26-1552AE0AB5E0Q44350349-3BE8D54A-4763-483E-8C4E-B3F767FA5A49Q44639804-99497F10-09E1-4EBD-A0EE-828905ABE617Q46794787-FC48F96D-D9FE-40F8-8F36-9624FA4DA5BEQ47909580-00ACB125-3A9B-4527-86C9-AF8574CD55CFQ48475595-A32B6C02-0E5E-4F5D-9EE4-8C3925A0C3C2Q49357267-10C4099B-FD9C-4113-8F9D-B87802BFBA0BQ50069510-5A57827E-E683-4CE2-A443-3E147983D6FA
P2860
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@ast
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@en
type
label
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@ast
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@en
prefLabel
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@ast
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@en
P2093
P2860
P1433
P1476
Distinct changes in cAMP and e ...... in L-DOPA-induced dyskinesia.
@en
P2093
Emanuela Santini
Gilberto Fisone
Marc Savasta
Veronique Sgambato-Faure
P2860
P304
P356
10.1371/JOURNAL.PONE.0012322
P407
P577
2010-08-23T00:00:00Z